PRIMO 2023 | Unanswered questions in screening for prostate cancer

Ravi Madan, MD, National Cancer Institute, Bethesda, MD, provides an overview of remaining issues relating to prostate cancer screening. Underdiagnosis in patients may result in an increase of metastatic prostate cancer. There is consequently a need for novel biomarkers in addition to PSA screening. This interview took place at the Practical Recommendations in Immuno and Molecular Oncology (PRIMO) 2023 Congress in Honolulu, HI.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.